Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma

Cancer

Volumn 82, Issue 5, 1998, Pages 957-964

  Kong, Lynn R ^a   Huang, Cheng Fang ^a   Hakimian, David ^a   Variakojis, Daina ^a   Klein, Leonard ^b   Kuzel, Timothy M ^a   Gordon, Leo I ^a   Zanzig, Connie ^a   Wollins, Eric ^a   Tallman, Martin S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

Author keywords

2 Chlorodeoxyadenosine; Cladribine; Non Hodgkin's lymphoma; Second malignancy

Indexed keywords

ALKYLATING AGENT; CLADRIBINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION; MALE; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SECOND CANCER;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CLADRIBINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFECTION; INFUSIONS, INTRAVENOUS; LYMPHOMA, LOW-GRADE; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032031650     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980301)82:5<957::AID-CNCR22>3.0.CO;2-Z     Document Type: Article

References (31)

1. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993;20:75-88.
2. Young RC, Longo DL, Glatstein E, Ihde DC, Jaffe ES, DeVita VT Jr. The treatment of indolent lymphomas: watchful waiting v. aggressive combined modality treatment. Semin Hematol 1988; 25 (Suppl 2):11-6.
3. Portlock CS. Management of low-grade non-Hodgkin's lymphomas. Semin Oncol 1990;17:51-9.
4. Ellis M, Lishner M. Second malignancies following treatment in non-Hodgkin's lymphoma. Leuk Lymphoma 1993;9:337-42.
5. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990;322:1117-21.
6. Juliusson G, Liliemark J. Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2′-deoxyadenosine (CdA): relation to opportunistic infections. Blood 1992;79:888-94.
7. Tallman MS, Hakimian D, Variakojis D, Koslow D, Sisney GA, Rademaker AW, et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 1992;9:2203-9.
8. Seymour JF, Kurzrock R, Freireich EJ, Estey EH. 2-Chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood 1994;83:2906-11.
9. Piro LD, Carrera CJ, Beutler E, Carson DA. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988;72:1069-73.
10. Juliusson G, Liliemark J. High complete remission rate from 2-chloro-2-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted be rapid decrease of blood lymphocyte count. J Clin Oncol 1993;11:679-89.
11. Tallman MS, Hakimian D, Zanzig C, Hogan DK, Rademaker AW, Rose E, et al. Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 1995;13:983-8.
12. Betticher DC, Fey MF, von Rohr A, Tobler A, Jenzer H, Gratwohl A, et al. High incidence of infections after 2-chlorodeoxyadenosine (2-CdA) therapy in patients with malignant lymphomas and chronic and acute leukemias. Ann Oncol 1994;5:57-64.
13. Dimopoulos MA, Kantarjian H, Estey E, O'Brien S, Delasalle K, Keating MJ, et al. Treatment of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 1993;118:195-8.
14. Dimopoulos MA, Kantarjian H, Weber D, O'Brien S, Estey E, Delasalle K, et al. Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeosyadenosine. J Clin Oncol 1994;12:2694-8.
15. Delannoy A, Ferrant A, Martiat P, Bosly A, Zenebergh A, Michaux JL. 2-Chlorodeoxyadenosine therapy in Waldenström's macroglobulinemia. Nouv Rev Fr Hematol 1994; 36:317-20.
16. Kuzel TM, Hurria A, Samuelson E, Tallman MS, Roenigk HH Jr., Rademaker AW, et al. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood 1996;87:906-11.
17. Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD. 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 1992;80:587-92.
18. Kay AC, Saven A, Carerra CJ, Carson DA, Thurston D, Beutler E, et al. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol 1992;10:371-7.
19. Hickish T, Serafinowski P, Cunningham D, Oza A, Darland E, Judson I, et al. 2-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. Br J Cancer 1993;67:139-43.
20. Hoffman M, Tallman MS, Hakimian D, Janson D, Hogan D, Variakojis D, et al. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. J Clin Oncol 1993;12:788-92.
21. Morton J, Taylor K, Bunce I, Eliadis P, Rentoul A, Moore D, et al. High response rates with short infusional 2-chlorodeoxyadenosine in de novo and relapsed low-grade lymphoma. Br J Haematol 1996;95:110-5.
22. National Cancer Institute sponsored study of classication of non-Hodgkin's lymphomas: summary and description of a Working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982;49:2112-35.
23. Rosner B. Fundamentals of biostatistics. 4th edition. Belmont, CA: Duxburg Press, 1995.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
25. Van Den Neste E, Delannoy A, Vandercam B, Bosly A, Ferrant A, Mineur P, et al. Infectious complications after 2-chlorodeoxyadenosine therapy. Eur J Haematol 1996;56:235-40.
26. O'Brien S, Kurzrock R, Duvic M, Kantarjian H, Stass S, Robertson LE, et al. 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood 1994;84:733-8.
27. Schlaifer D, Rigal-Huguet F, Pris J, Brousset P, Delannoy A, Bosly A. Secondary neoplasms in two patients treated with purine analogues [letter]. Nouv Rev Fr Hematol 1994;36:341.
28. Horning SJ, Rosenberg SA. The natural historyof initially untreated low-grade non-Hodgkin's lymphoma. N Engl J Med 1984;311:1471-5.
29. Saven A, Emanuele S, Kosty M, Koziol J, Ellison D, Piro L. 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blood 1995;86:1710-6.
30. Betticher DC, Zucca E, von Rohr A, Egger T, Radford JA, Ambrosetti A, et al. 2-Chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma. Ann Oncol 1996;7:793-9.
31. Saven A, Lee T, Kosty M, Piro L. Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma. J Clin Oncol 1996;14:2139-44.